Virpax Pharmaceuticals Inc - VRPX STOCK NEWS

Virpax Pharmaceuticals (NASDAQ: VRPX), a company focused on developing non-addictive products for pain management, PTSD, CNS disorders, and anti-viral barrier indications, announced that Matthew Barnes, senior director of portfolio management, will present at the Outsourcing in Clinical Trials Conference. The OCT series is a prominent conference bringing together over 1,000 industry leaders annually to discuss clinical trial optimization and cost management.

Additionally, the company announced that Dr. Sheila Mathias (Chief Scientific Officer) and Matthew Barnes have published two articles in the DIA Global Forum and one article in the OCT Handbook 2025.

Virpax Pharmaceuticals (NASDAQ: VRPX) has announced the closing of a $6.0 million public offering of common stock and pre-funded warrants. The offering price was set at $0.20 per share (minus $0.00001 per pre-funded warrant). The proceeds will be used to fund clinical trial development for their product candidate Probudur, marketing and advertising services for financial community communications, working capital, and other general corporate purposes.

Spartan Capital Securities, served as the exclusive placement agent for the offering. The securities were offered through a registration statement on Form S-1, which was filed with the SEC on July 29, 2024, amended on January 15 and 17, 2025, and declared effective on January 27, 2025.

Virpax Pharmaceuticals (Nasdaq: VRPX) has announced the pricing of a $6 million public offering of common stock and pre-funded warrants. The offering includes shares priced at $0.20 and pre-funded warrants at $0.19999 per share.

The proceeds will be used to fund ongoing development activities for the clinical trial of Probudur, marketing and advertising services for financial community communications, working capital, and general corporate purposes. Spartan Capital Securities is serving as the exclusive placement agent.

The offering is expected to close on January 29, 2025, subject to customary conditions, and is being conducted under the Company's Form S-1 registration statement, which was declared effective by the SEC on January 27, 2025.

Virpax Pharmaceuticals (NASDAQ: VRPX) announced positive results from a minipig Dose Range Finding study for Probudur, their long-acting liposomal bupivacaine formulation for pain management. The study evaluated Probudur's tolerance in an incisional wound healing model, with all minipigs showing positive tolerance and no adverse effects. Preclinical studies demonstrated pain control lasting up to 96 hours, with rat models showing analgesia for up to five days and in vitro studies showing bupivacaine release for up to six days. Probudur aims to provide immediate and extended pain relief while reducing or eliminating post-surgical opioid needs.

Virpax Pharmaceuticals (NASDAQ: VRPX) has secured an extension of its cooperative research agreement with the National Center for Advancing Translational Sciences (NCATS) for developing NES100, an intranasal peptide for acute and chronic non-cancer pain management. NES100 uses nanotechnology to deliver enkephalin, a natural peptide, to the brain via a nasal route. The technology aims to suppress pain by binding to delta opioid receptors without the adverse effects typically associated with opioids, such as tolerance, withdrawal, respiratory depression, euphoria, or addiction. Animal models have shown promising analgesic potential.

Virpax Pharmaceuticals (VRPX) has closed a $5.0 million public offering of common stock and pre-funded warrants at $0.50 per share. The proceeds will fund the company's ongoing activities, including an IND filing for Probudur™, their proprietary patented injectable local anesthetic liposomal technology for post-operative pain management. Funds will also cover marketing services through IR Agency and general corporate purposes. Spartan Capital Securities acted as the exclusive placement agent for the offering.

Virpax Pharmaceuticals (NASDAQ: VRPX) has announced the pricing of a $5.0 million public offering of common stock and pre-funded warrants at $0.50 per share. The proceeds will fund the company's ongoing activities, including its planned IND filing for ProbudurTM, a proprietary patented injectable local anesthetic liposomal technology for post-operative pain management. The offering, managed by Spartan Capital Securities as exclusive placement agent, is expected to close on November 14, 2024. The offering is conducted under the company's Form S-1 registration statement, which was declared effective by the SEC on November 12, 2024.

Virpax Pharmaceuticals (NASDAQ: VRPX) reported its Q2 2024 financial results and recent developments. Key highlights include:

• Positive results from a pharmacokinetics and safety study for Probudur, their lead asset for pain relief
• Secured $2.8 million from warrant exercises and a $2.5 million loan (repaid) to settle litigation
• Regained Nasdaq compliance for minimum bid price
• Q2 operating loss of $3.5 million, up from $3.1 million in Q2 2023
• R&D expenses increased to $2.0 million, primarily due to Probudur preclinical activities
• G&A expenses decreased to $1.5 million
• Cash balance of $1.9 million as of June 30, 2024

The company remains focused on advancing its product candidates and exploring licensing opportunities.

Virpax Pharmaceuticals (NASDAQ: VRPX), a company focused on developing non-addictive products for pain management, PTSD, CNS disorders, and anti-viral barrier indications, has announced its participation in the Sidoti August Virtual Investor Conference on August 14-15, 2024. CEO Gerald W. Bruce and CFO Vinay Shah will represent the company.

Key points:

• Bruce will present on August 14th at 2:30 PM (ET)
• The presentation will be accessible live via a provided link
• Virpax will host one-on-one meetings with investors on both conference days
• Registration for the event is free and open to all, not to Sidoti clients

This conference provides an opportunity for Virpax to showcase its innovative product pipeline and engage with potential investors.